|
|
|
|
Increasing Competition From Other Biologic Agents Will Continue to Erode Enbrel's Dominance in the Psoriasis D
WALTHAM, Mass., Feb.10 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, owing to increasing competition from other biologic agents, Amgen/Pfizer/Takeda's Enbrel ...
|
|
|
Biopharmaceuticals: saving the future of our industry
Pharmaceutical Technology Europe Volume 22, Issue 2 (COLIN ANDERSON/) Biopharmaceuticals are becoming increasingly prominent in the pharmaceutical industry and are expected to dominate product use and sales of the future.Research released by PharmaVision in...
|
|
|
Elderkin team leaves Woodcock Washburn for Akin Gump
Three partners from intellectual property law firm Woodcock Washburn, including former policy committee member and current litigation practice chairwoman Dianne Elderkin, have decided to join Akin Gump Strauss Hauer & Felds Philadelphia office.Joining...
|
|
|
Elderkin team leaves Woodcock Washburn for Akin Gump
Three partners from intellectual property law firm Woodcock Washburn, including former policy committee member and current litigation practice chairwoman Dianne Elderkin, have decided to join Akin Gump Strauss Hauer & Felds Philadelphia office.Joining...
|
|
|
Elderkin team leaves Woodcock Washburn for Akin Gump
Three partners from intellectual property law firm Woodcock Washburn, including former policy committee member and current litigation practice chairwoman Dianne Elderkin, have decided to join s Philadelphia office.Joining Elderkin at Washington, D.C.-based...
|
|
|
Pfizer's Hedge Pays Off
Recs 0 //Create your sharelet with desired properties and set button element to false object //Tie customized button to This button functionality.element Disney Buys Marvel! David Gardner called it! Hes up 1,334%! See what Davids recommending that you...
|
|
|
Elderkin team leaves Woodcock Washburn for Akin Gump
Three partners from intellectual property law firm Woodcock Washburn, including former policy committee member and current litigation practice chairwoman Dianne Elderkin, have decided to join s Philadelphia office.Joining Elderkin at Washington, D.C.-based...
|
|
|
Pfizer's Hedge Pays Off
You almost want to say that Pfizer (NYSE: PFE) saw this coming.When the drug giant licensed Protalix BioTherapeutics' (NYSE: PLX) Gaucher disease treatment, taliglucerase alfa, two months ago, I characterized the license as a steal. Turns out Pfizer's low...
|
|
|
Biomarker could help doctors tailor treatment for rheumatoid arthritis
The study, led by researchers at Hospital for Special Surgery in collaboration with rheumatologists at University of Southern California, appears in the February issue of the journal Arthritis & Rheumatism.'While our study was performed on a relatively...
|
|
|
Research and Markets: The Biotech Company League Table: Fortunes of the Top 100 Biotech Companies Involved in Human Healthcare on the Basis of Product
45 AM DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/e308ab/the_biotech_compan) has announced the addition of the "The Biotech Company League Table" report to their offering.The worlds first biotechnology company,...
|
|
|
Biomarker Could Help Doctors Tailor Treatment for Rheumatoid Arthritis
Investigators have identified a biomarker that could help doctors select patients with rheumatoid arthritis who will benefit from therapy with drugs such as Enbrel, a tumor necrosis factor (TNF)-antagonist drug.The study, led by researchers at in...
|
|
|
Global Pharmaceutical Biotech Market 2010-2025 - New Market Report Published
The global pharmaceutical biotech market continues to experience high growth, with developers ranging from major pharmaceutical companies to specialist pharmaceutical firms.Significant R&D efforts and innovative new treatments will lead to further...
|
|
|
Biomarker Could Help Doctors Tailor Treatment For Rheumatoid Arthritis
Investigators have identified a biomarker that could help doctors select patients with rheumatoid arthritis who will benefit from therapy with drugs such as Enbrel, a tumor necrosis factor (TNF)-antagonist drug.The study, led by researchers at Hospital for...
|
|
|
Biomarker could help doctors tailor treatment for rheumatoid arthritis
Investigators have identified a biomarker that could help doctors select patients with rheumatoid arthritis who will benefit from therapy with drugs such as Enbrel, a tumour necrosis factor (TNF)-antagonist drug.The study, led by researchers at in...
|
|
|
Global Pharmaceutical Biotech Market 2010-2025
The global pharmaceutical biotech market continues to experience high growth, with developers ranging from major pharmaceutical companies to specialist pharmaceutical firms.Significant R&D efforts and innovative new treatments will lead to further...
|
|
|
Global Pharmaceutical Biotech Market 2010-2025
The global pharmaceutical biotech market continues to experience high growth, with developers ranging from major pharmaceutical companies to specialist pharmaceutical firms.Significant R&D efforts and innovative new treatments will lead to further...
|
|
|
Global Pharmaceutical Biotech Market 2010-2025 by Bharatbook
Bharatbook.com added a new report on "Global Pharmaceutical Biotech Market 2010-2025" which gives Comprehensive analysis of the global biopharma market.FOR IMMEDIATE RELEASE PR Log (Press Release) Jan 30, 2010 Global Pharmaceutical Biotech Market 2010-2025...
|
|
|
New biomarker may predict treatment outcomes in RA patients
Investigators have identified a biomarker that could help doctors select patients with rheumatoid arthritis who will benefit from therapy with drugs such as Enbrel, a tumor necrosis factor (TNF)-antagonist drug.The study, led by researchers at Hospital for...
|
|
|
Abbott profit stays flat in 4Q
ABBOTT PARK -- Abbott Laboratories says its fourth-quarter profit was flat on higher costs, but sales of the drug Humira continue to drive revenue.The company on Wednesday reported $1.54 million, or 98 cents per share, in profit during the quarter,...
|
|
|
Biomarker could help doctors tailor treatment for rheumatoid arthritis
ScienceDaily (Jan.29, 2010) Investigators have identified a biomarker that could help doctors select patients with rheumatoid arthritis who will benefit from therapy with drugs such as Enbrel, a tumor necrosis factor (TNF)-antagonist drug. The study, led...
|
|
|
Biomarker could help doctors tailor treatment for rheumatoid arthritis
Investigators have identified a biomarker that could help doctors select patients with rheumatoid arthritis who will benefit from therapy with drugs such as Enbrel, a tumor necrosis factor (TNF)-antagonist drug.The study, led by researchers at Hospital for...
|
|
|
Biomarker could help doctors tailor treatment for rheumatoid arthritis
Investigators have identified a biomarker that could help doctors select patients with rheumatoid arthritis who will benefit from therapy with drugs such as Enbrel, a tumor necrosis factor (TNF)-antagonist drug.The study, led by researchers at in...
|
|
|
Biomarker Could Help Doctors Tailor Treatment for Rheumatoid Arthritis
Source: Hospital for Special Surgery Newswise Investigators have identified a biomarker that could help doctors select patients with rheumatoid arthritis who will benefit from therapy with drugs such as Enbrel, a tumor necrosis factor (TNF)-antagonist drug.
|
|
|
Biomarker Could Help Doctors Tailor Treatment for Rheumatoid Arthritis
Newswise - Investigators have identified a biomarker that could help doctors select patients with rheumatoid arthritis who will benefit from therapy with drugs such as Enbrel, a tumor necrosis factor (TNF)-antagonist drug.The study, led by researchers at...
|
|
|
Abbott sales jump, but Humira sales weigh on stock
* Q4 EPS ex-items $1.18; Street view $1.17 * Sales rise almost 11 pct to $8.79 billion * Shares off 1.5 pct, weak Humira sales weigh * Company forecasts 2010 Humira growth in 20 pct range NEW YORK (Reuters) - Abbott Laboratories reported stronger...
|
